TRANSTHERA-B Shares Drop Over 3% Following Third Fundraising via Discounted Placement This Year

Stock News11:24

TRANSTHERA-B (02617) experienced significant volatility in its share price this morning. The stock initially plunged over 9% to an intraday low of HKD 45.24 before staging a strong rebound to HKD 53.8. The share price has since retreated again. As of the latest update, the stock is down 3.14%, trading at HKD 48.24, with a turnover of HKD 129 million.

The company announced plans this morning to place approximately 3.836 million new shares to no fewer than six placees, representing about 0.94% of the enlarged share capital. The placement price is set at HKD 40.83 per share, representing a discount of roughly 18.01% to the closing price of HKD 49.8 on May 18.

Assuming the placement shares are fully subscribed, the gross proceeds are estimated at approximately HKD 157 million, with net proceeds of about HKD 152 million. Approximately 90% of the net proceeds are earmarked for the development of new indications for the company's core product, Tinengotinib. The remaining 10% is intended for general working capital and corporate purposes.

This placement marks the third fundraising activity undertaken by TRANSTHERA-B within the current year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145272584?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 11:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145272584","market":"nz","top_or_hot":-1,"title":"TRANSTHERA-B Shares Drop Over 3% Following Third Fundraising via Discounted Placement This Year","media":"Stock News","content":"<p>TRANSTHERA-B (02617) experienced significant volatility in its share price this morning. The stock initially plunged over 9% to an intraday low of HKD 45.24 before staging a strong rebound to HKD 53.8. The share price has since retreated again. As of the latest update, the stock is down 3.14%, trading at HKD 48.24, with a turnover of HKD 129 million.</p>\n<p>The company announced plans this morning to place approximately 3.836 million new shares to no fewer than six placees, representing about 0.94% of the enlarged share capital. The placement price is set at HKD 40.83 per share, representing a discount of roughly 18.01% to the closing price of HKD 49.8 on May 18.</p>\n<p>Assuming the placement shares are fully subscribed, the gross proceeds are estimated at approximately HKD 157 million, with net proceeds of about HKD 152 million. Approximately 90% of the net proceeds are earmarked for the development of new indications for the company's core product, Tinengotinib. The remaining 10% is intended for general working capital and corporate purposes.</p>\n<p>This placement marks the third fundraising activity undertaken by TRANSTHERA-B within the current year.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TRANSTHERA-B Shares Drop Over 3% Following Third Fundraising via Discounted Placement This Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTRANSTHERA-B Shares Drop Over 3% Following Third Fundraising via Discounted Placement This Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-19 11:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TRANSTHERA-B (02617) experienced significant volatility in its share price this morning. The stock initially plunged over 9% to an intraday low of HKD 45.24 before staging a strong rebound to HKD 53.8. The share price has since retreated again. As of the latest update, the stock is down 3.14%, trading at HKD 48.24, with a turnover of HKD 129 million.</p>\n<p>The company announced plans this morning to place approximately 3.836 million new shares to no fewer than six placees, representing about 0.94% of the enlarged share capital. The placement price is set at HKD 40.83 per share, representing a discount of roughly 18.01% to the closing price of HKD 49.8 on May 18.</p>\n<p>Assuming the placement shares are fully subscribed, the gross proceeds are estimated at approximately HKD 157 million, with net proceeds of about HKD 152 million. Approximately 90% of the net proceeds are earmarked for the development of new indications for the company's core product, Tinengotinib. The remaining 10% is intended for general working capital and corporate purposes.</p>\n<p>This placement marks the third fundraising activity undertaken by TRANSTHERA-B within the current year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1145272584","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145272584","pubTimestamp":1779161061,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TRANSTHERA-B (02617) experienced significant volatility in its share price this morning. The stock initially plunged over 9% to an intraday low of HKD 45.24 before staging a strong rebound to HKD...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","02617":"药捷安康-B","VXUS":"国际股票ETF-Vanguard"},"translate_title":"TRANSTHERA-B今年第三次通过折扣配售融资后股价下跌超过3%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"02617":1},"content_text":"TRANSTHERA-B (02617) experienced significant volatility in its share price this morning. The stock initially plunged over 9% to an intraday low of HKD 45.24 before staging a strong rebound to HKD 53.8. The share price has since retreated again. As of the latest update, the stock is down 3.14%, trading at HKD 48.24, with a turnover of HKD 129 million.\nThe company announced plans this morning to place approximately 3.836 million new shares to no fewer than six placees, representing about 0.94% of the enlarged share capital. The placement price is set at HKD 40.83 per share, representing a discount of roughly 18.01% to the closing price of HKD 49.8 on May 18.\nAssuming the placement shares are fully subscribed, the gross proceeds are estimated at approximately HKD 157 million, with net proceeds of about HKD 152 million. Approximately 90% of the net proceeds are earmarked for the development of new indications for the company's core product, Tinengotinib. The remaining 10% is intended for general working capital and corporate purposes.\nThis placement marks the third fundraising activity undertaken by TRANSTHERA-B within the current year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145272584","isCrawlerRequest":true}